Ubs Group Ag Lexaria Bioscience Corp. Transaction History

Ubs Group Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$0.92 - $1.69 $4,169 - $7,659	4,532 New	4,532 $5,000
Q2 2023 Aug 11, 2023	SELL	$0.69 - $2.69 $3,132 - $12,212	-4,540 Reduced 97.87%	99 $0
Q1 2023 May 12, 2023	SELL	$2.47 - $3.47 $2,363 - $3,320	-957 Reduced 17.1%	4,639 $12,000
Q4 2022 Feb 08, 2023	SELL	$1.95 - $2.98 $1,563 - $2,389	-802 Reduced 12.54%	5,596 $13,000
Q3 2022 Nov 10, 2022	BUY	$0.74 - $3.28 $1,647 - $7,304	2,227 Added 53.39%	6,398 $16,000
Q2 2022 Aug 10, 2022	BUY	$1.88 - $4.06 $2,835 - $6,122	1,508 Added 56.63%	4,171 $12,000
Q1 2022 May 16, 2022	SELL	$2.78 - $4.7 $4,089 - $6,913	-1,471 Reduced 35.58%	2,663 $9,000
Q4 2021 Feb 14, 2022	BUY	$3.87 - $6.9 $15,998 - $28,524	4,134 New	4,134 $17,000

1.06M

Ticker LEXX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,951,000
Market Cap $12.8M
Description
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x ...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.